Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hangzhou Jitai Pharmaceutical Technology Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, WERTZ, ASHLEE ELIZABETH. The prosecution is occurring within 1 distinct art unit, which indicates a highly focused technical review for the company's current biotechnology assets. Such concentration is common when a portfolio is built around a specific core innovation.
WERTZ, ASHLEE ELIZABETH is the busiest examiner for the portfolio, managing 1 busiest examiner pending action. This single action accounts for the total 1 pending office action currently active. The concentration in a single examiner and art unit suggests a streamlined examination path. For the practitioner, this means that the specific preferences of the assigned examiner will be the primary factor in the success of the 1 pending office action within the Biotechnology & Pharmaceuticals sector. By focusing on the requirements of WERTZ, ASHLEE ELIZABETH, the company can tailor its responses to address the specific concerns raised in the pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WERTZ, ASHLEE ELIZABETH | 1 | 52.7% | +35.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688308 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | WERTZ, ASHLEE ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18688308 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | WERTZ, ASHLEE ELIZABETH | 1612 | §103 | Final Rejection | — | Pending | Feb 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHangzhou Jitai Pharmaceutical Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ashlee Elizabeth Wertz has the most, with 1 of Hangzhou Jitai Pharmaceutical Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
